Securities Star Data Center News, Tiankang Bio 2021 interim report shows that the company's main revenue of 7.917 billion yuan, up 68.32% year-on-year; net profit attributable to the mother of 241 million yuan, down 71.05% year-on-year; deduction of non-net profit of 264 million yuan, down 69.19% year-on-year; debt ratio of 52.67%, investment income of 23.4178 million yuan, financial expenses of 105 million yuan, gross profit margin of 18.13%.
There are 3 new shareholders in this period, Xinjiang Tianbang Hongkang Venture Capital Co., Ltd. holds 62,580,733 shares, accounting for 5.81% of the outstanding shares, He Sheng holds 4.451 million shares, accounting for 0.41% of the outstanding shares, Xinjiang Academy of Animal Sciences holds 28,499,744 shares, accounting for 2.65% of the outstanding shares; a total of 1 shareholder increases its shareholding, Wang Xiangpai increases its shareholding by 419,000 shares, and the shareholder holds 0.37% of the circulating shares; a total of 2 shareholders reduce their holdings. Zhu Wentao reduced his holdings by 15,300 shares, the shareholder held 1.12% of the outstanding shares, and the Hong Kong Securities Clearing Company Limited reduced its holdings by 1,280,313 shares, and the shareholder held 0.46% of the outstanding shares;
For a summary of the financial report data, please see the following figure:
![Jilin Ruikang Biotechnology Co., Ltd.: Rely on "digging treasure" to seek development, seek innovation and change, and create the future[fig]](data:image/gif;base64,R0lGODlhAQABAIAAAP///wAAACwAAAAAAQABAAACAkQBADs=)